TSE:CPH Cipher Pharmaceuticals (CPH) Stock Price, News & Analysis → Did you make $29,000 two days with AI options trades? (From Prosper Trading Academy) (Ad) Free CPH Stock Alerts C$9.27 -0.23 (-2.42%) (As of 03/27/2024 ET) Add Compare Share Share Today's RangeC$9.12▼C$9.5050-Day RangeC$5.60▼C$9.5052-Week RangeC$3.11▼C$9.98Volume47,609 shsAverage Volume38,455 shsMarket CapitalizationC$222.39 millionP/E Ratio8.50Dividend YieldN/APrice TargetC$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlines Get Cipher Pharmaceuticals alerts: Email Address Ad Prosper Trading AcademyDid you make $29,000 two days with AI options trades?What if it was possible to find options trades on autopilot… Using A.I. to find the ones with the highest profit potential… And nearly perfect win rates… You can grab your free copy of my "Ultimate Guide to A.I. Options Trading" by clicking the link below:Click Here To Get Your Free Copy About Cipher Pharmaceuticals Stock (TSE:CPH)Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome. The company's licensed products comprise Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne; Lipofe indicated as adjunctive therapy to diet to reduce triglycerides in adult patients with severe hypertriglyceridemia; and Conzip, an opioid agonist indicated for the management of moderate to moderately severe chronic pain in adults. Its pipeline products include CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Mississauga, Canada.Read More CPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CPH Stock News HeadlinesMarch 17, 2024 | seekingalpha.comCipher Pharmaceuticals (CPHRF) Q4 2023 Earnings Call TranscriptMarch 17, 2024 | investing.comEarnings call: Cipher Pharmaceuticals outlines growth and financialsMarch 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.January 5, 2024 | morningstar.comCipher Pharmaceuticals Inc CPHJanuary 3, 2024 | finance.yahoo.comCipher Pharmaceuticals Inc (PHE.MU)November 24, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Change of AuditorNovember 24, 2023 | benzinga.comCipher Pharmaceuticals Stock (OTC:CPHRF) Dividends: History, Yield and DatesNovember 15, 2023 | finance.yahoo.comCipher Pharmaceuticals Inc.'s (TSE:CPH) 23% gain last week benefited both individual investors who own 56% as well as insidersMarch 28, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.October 27, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q3 2023 Earnings Release and Conference CallSeptember 5, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Intention to Commence Substantial Issuer Bid, Aggregate Price up to $6 Million Canadian DollarsAugust 10, 2023 | finance.yahoo.comCipher Pharmaceuticals Releases Q2 2023 Results, Announces Launch of Epuris in MexicoJuly 28, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q2 2023 Earnings Release and Conference CallJuly 5, 2023 | finance.yahoo.comCipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European UnionJune 21, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Results of Annual and Special Meeting of ShareholdersMay 4, 2023 | finance.yahoo.comCipher Pharmaceuticals Schedules Q1 2023 Earnings Release and Conference CallApril 26, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Tuesday (CPH)April 20, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc flat on Thursday (CPH)April 18, 2023 | finanznachrichten.deBloom Burton & Co. Inc.: Cipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 18, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Tuesday (CPH)April 18, 2023 | finance.yahoo.comCipher Pharmaceuticals to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 14, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc up on Friday (CPH)April 10, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Monday (CPH)April 6, 2023 | theglobeandmail.comClosing Bell: Cipher Pharmaceuticals Inc down on Wednesday (CPH)March 19, 2023 | seekingalpha.comCipher Pharmaceuticals Non-GAAP EPS of -$0.12March 16, 2023 | finance.yahoo.comCipher Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 1, 2023 | finance.yahoo.comCipher Pharmaceuticals Announces Closing of New US$35 Million Credit FacilitySee More Headlines Receive CPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cipher Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today3/28/2024Next Earnings (Estimated)5/09/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeTSE SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolTSE:CPH Previous SymbolTSE:DND CUSIPN/A CIKN/A Webwww.cipherpharma.com Phone+1-905-6025840FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price TargetC$8.00 High Stock Price TargetC$8.00 Low Stock Price TargetC$8.00 Potential Upside/Downside-13.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)C$1.09 Trailing P/E Ratio8.50 Forward P/E Ratio15.06 P/E GrowthN/ANet IncomeC$20.38 million Net Margins96.32% Pretax MarginN/A Return on Equity28.19% Return on Assets8.06% Debt Debt-to-Equity Ratio0.44 Current Ratio9.19 Quick Ratio2.67 Sales & Book Value Annual SalesC$21.16 million Price / Sales10.51 Cash FlowC$2.63 per share Price / Cash Flow3.53 Book ValueC$3.36 per share Price / Book2.76Miscellaneous Outstanding Shares23,990,000Free FloatN/AMarket CapC$222.39 million OptionableNot Optionable Beta0.97 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Craig J. MullInterim CEO & Chairman of the BoardMr. Bryan JacobsChief Financial OfficerDr. Diane GajewczykVice President of Scientific & Medical AffairsMr. Emilio PrestiDirector of Sales & MarketingKey CompetitorsICC LabsCVE:ICCESSA PharmaCVE:EPIRIV CapitalTSE:RIVLeaf MobileTSE:LEAFSupreme CannabisTSE:FIREView All Competitors CPH Stock Analysis - Frequently Asked Questions Should I buy or sell Cipher Pharmaceuticals stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" CPH shares. View CPH analyst ratings or view top-rated stocks. What is Cipher Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued 1 year price objectives for Cipher Pharmaceuticals' shares. Their CPH share price targets range from C$8.00 to C$8.00. On average, they predict the company's stock price to reach C$8.00 in the next twelve months. This suggests that the stock has a possible downside of 13.7%. View analysts price targets for CPH or view top-rated stocks among Wall Street analysts. How have CPH shares performed in 2024? Cipher Pharmaceuticals' stock was trading at C$5.54 at the start of the year. Since then, CPH shares have increased by 67.3% and is now trading at C$9.27. View the best growth stocks for 2024 here. When is Cipher Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CPH earnings forecast. How were Cipher Pharmaceuticals' earnings last quarter? Cipher Pharmaceuticals Inc. (TSE:CPH) posted its earnings results on Thursday, March, 14th. The company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.15 by $0.26. The firm had revenue of $6.70 million for the quarter, compared to analyst estimates of $7.31 million. Cipher Pharmaceuticals had a trailing twelve-month return on equity of 28.19% and a net margin of 96.32%. What other stocks do shareholders of Cipher Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cipher Pharmaceuticals investors own include Cipher Pharmaceuticals (CPHRF), Bellatrix Exploration (BXE), Aurora Cannabis (ACB), Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Catalyst Biosciences (CBIO), Crescent Point Energy (CPG) and Enbridge (ENB). How do I buy shares of Cipher Pharmaceuticals? Shares of CPH stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.Compare Top Brokerages Here. This page (TSE:CPH) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBREAKING: New AI Breakthrough Could Change Healthcare ForeverBehind the Markets“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cipher Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.